Finanzen von DarioHealth Corp (DRIO)DRIODarioHealth Corp

Evaluating the bottom line, DarioHealth Corp maintains a gross margin of 61.66%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -125.15%, while the net margin is -153.06%. These profitability ratios, combined with a Return on Equity (ROE) of -104.37%, provide a clear picture of how effectively DRIO converts its operational activities into shareholder value.

In the context of the broader market, DRIO competes directly with industry leaders such as NSYS and RMTI. With a market capitalization of $23.72M, it holds a significant position in the sector. When comparing efficiency, DRIO's gross margin of 61.66% stands against NSYS's 17.00% and RMTI's 18.24%. Such benchmarking helps identify whether DarioHealth Corp is trading at a premium or discount relative to its financial performance.

DarioHealth has shown a gross margin of 61.66% in Q2 2026, indicating strong profitability on sales, but it continues to report substantial net losses, with a net income of -$7.92 million in the same quarter.